Increasing the predictive accuracy of amyloid-β blood-borne biomarkers in alzheimer's disease

Journal of Alzheimer's Disease

Volumn 24, Issue 1, 2011, Pages 47-59

  Watt, Andrew D ^a,b   Perez, Keyla A ^a,b   Faux, Noel G ^a   Pike, Kerryn E ^a,c   Rowe, Christopher C ^c,d   Bourgeat, Pierrick ^e   Salvado, Olivier ^e   Masters, Colin L ^a   Villemagne, Victor L ^a,c,d   Barnham, Kevin J ^a,b  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c Austin Health ^*  (Australia)

^d AUSTIN HEALTH   (Australia)

^e CSIRO   (Australia)

Author keywords

Amyloid ; biomarkers; blood; copper; diagnostics; SELDI TOF MS

Indexed keywords

AMYLOID BETA PROTEIN; BIOLOGICAL MARKER;

AGED; ALZHEIMER DISEASE; ARTICLE; BRAIN SIZE; CELL FRACTIONATION; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE SEVERITY; FEMALE; HIPPOCAMPUS; HUMAN; IMMOBILIZED METAL AFFINITY CHROMATOGRAPHY; MALE; MEMORY; MILD COGNITIVE IMPAIRMENT; MINI MENTAL STATE EXAMINATION; PRIORITY JOURNAL; PROTEOMICS; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY;

EID: 79955650319     PISSN: 13872877     EISSN: None     Source Type: Journal    
DOI: 10.3233/JAD-2010-101722     Document Type: Article

References (54)

1. Blennow K, de Leon MJ, Zetterberg H (2006) Alzheimer's disease. Lancet 368, 387-403. (Pubitemid 44108123)
2. American Psychiatric Association (2000) Diagnostic and Statistical Manual of Mental Disorders (IV-TR), Washington, DC.
3. Villemagne VL, Perez KA, Pike KE, Kok WM, Rowe CC, White AR, Bourgeat P, Salvado O, Bedo J, Hutton CA, Faux NG, Masters CL, Barnham KJ (2010) Blood borne amyloidbeta dimer correlates with clinical markers of Alzheimer's disease. J Neurosci 30, 6315-6322.
4. Masters CL, Cappai R, Barnham KJ, Villemagne VL (2006) Molecular mechanisms for Alzheimer's disease: implications for neuroimaging and therapeutics. J Neurochem 97, 1700-1725. (Pubitemid 43873662)
5. Jellinger KA, Janetzky B, Attems J, Kienzl E (2008) Biomark-ers for early diagnosis of Alzheimer disease: 'Alzheimer Associated gene'-A new blood biomarker? J Cell Mol Med 12, 1094-1117.
6. Dubois B, Feldman HH, Jacova C, Dekosky ST, Barberger-Gateau P, Cummings J, Delacourte A, Galasko D, Gauthier S, Jicha G, Meguro K, O'Brien J, Pasquier F, Robert P, Rossor M, Salloway S, Stern Y, Visser PJ, Scheltens P (2007) Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol 6, 734-746. (Pubitemid 47058377)
7. Fagan AM, Mintun MA, Mach RH, Lee SY, Dence CS, Shah AR, LaRossa GN, Spinner ML, Klunk WE, Mathis CA, DeKosky ST, Morris JC, Holtzman DM (2006) Inverse rela-tion between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann Neurol 59, 512-519. (Pubitemid 43358072)
8. Hansson O, Zetterberg H, Buchhave P, Andreasson U, Londos E, Minthon L, Blennow K (2007) Prediction of Alzheimer's disease using the CSF Abeta42/Abeta40 ratio in patients with mild cognitive impairment. Dement Geriatr Cogn Disord 23, 316-320. (Pubitemid 46631938)
9. De Meyer G, Shapiro F, Vanderstichele H, Vanmechelen E, Engelborghs S, De Deyn PP, Coart E, Hansson O, Minthon L, Zetterberg H, Blennow K, Shaw L, Trojanowski JQ (2010) Diagnosis-independent Alzheimer disease biomarker signa-ture in cognitively normal elderly people. Arch Neurol 67, 949-956.
10. Klunk WE, Engler H, Nordberg A, Wang YM, Blomqvist G, Holt DP, Bergstrom M, Savitcheva I, Huang GF, Estrada S, Ausen B, Debnath ML, Barletta J, Price JC, Sandell J, Lopresti BJ, Wall A, Koivisto P, Antoni G, Mathis CA, Langstrom B (2004) Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol 55, 306-319. (Pubitemid 38269583)
11. Rowe CC, Ng S, Ackermann U, Gong SJ, Pike K, Savage G, Cowie TF, Dickinson KL, Maruff P, Darby D, Smith C, Woodward M, Merory J, Tochon-Danguy H, O'Keefe G, Klunk WE, Mathis CA, Price JC, Masters CL, Villemagne VL (2007) Imaging beta-amyloid burden in aging and dementia. Neurology 68, 1718-1725. (Pubitemid 46763260)
12. Shaw LM, Vanderstichele H, Knapik-Czajka M, Clark CM, Aisen PS, Petersen RC, Blennow K, Soares H, Simon A, Lewczuk P, Dean R, Siemers E, Potter W, Lee VMY, Trojanowski JQ, Alzheimer's Dis Neuroimaging I (2009) Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann Neurol 65, 403-413.
13. Vemuri P, Wiste HJ, Weigand SD, Shaw LM, Trojanowski JQ, Weiner MW, Knopman DS, Petersen RC, Jack CR Jr; On behalf of the Alzheimer's Disease Neuroimaging Initia-tive (2009) MRI and CSF biomarkers in normal, MCI, and AD subjects: Diagnostic discrimination and cognitive corre-lations. Neurology 73, 287-293.
14. Lautenschlager NT, Riemenschneider M, Drzezga A, Kurz AF (2001) Primary degenerative mild cognitive impairment: Study population, clinical, brain imaging and biochemical findings. Dement Geriatr Cogn Disord 12, 379-386. (Pubitemid 34701661)
15. Andreasen N, Vanmechelen E, Vanderstichele H, Davidsson P, Blennow K (2003) Cerebrospinal fluid levels of total-tau, phospho-tau and Ab42 predicts development of Alzheimer's disease in patients with mild cognitive impairment. Acta Neurol Scand Suppl 179, 47-51.
16. Hansson O, Zetterberg H, Buchhave P, Londos E, Blennow K, Minthon L (2006) Association between CSF biomark-ers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol 5, 228-234. (Pubitemid 43238346)
17. Mattsson N, Zetterberg H, Hansson O, Andreasen N, Parnetti L, Jonsson M, Herukka S-K, van der Flier WM, Blankenstein MA, Ewers M, Rich K, Kaiser E, Verbeek M, Tsolaki M, Mulugeta E, Rosen E, Aarsland D, Visser PJ, Schroder J, Marcusson J, de Leon M, Hampel H, Scheltens P, Pirttila T, Wallin A, Jonhagen ME, Minthon L, Winblad B, Blennow K (2009) CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA 302, 385-393.
18. Li Y, Rinne JO, Mosconi L, Pirraglia E, Rusinek H, DeSanti S, Kemppainen N, Nagren K, Kim BC, Tsui W, de Leon MJ (2008) Regional analysis of FDG and PIB-PET images in normal aging, mild cognitive impairment, and Alzheimer's disease. Eur J Nucl Med Mol Imaging 35, 2169-2181.
19. Mikhno A, Devanand D, Pelton G, Cuasay K, Gunn R, Upton N, Lai RY, Libri V, Mann JJ, Parsey RV (2008) Voxel-based analysis of C-11-PIB scans for diagnosing Alzheimer's dis-ease. J Nucl Med 49, 1262-1269.
20. Ng S, Villemagne VL, Berlangieri S, Lee ST, Cherk M, Gong SJ, Ackermann U, Saunder T, Tochon-Danguy H, Jones G, Smith C, O'Keefe G, Masters CL, Rowe CC (2007) Visual assessment versus quantitative assessment of C-11-PIB PET and F-18-FDG PET for detection of Alzheimer's disease. J Nucl Med 48, 547-552. (Pubitemid 47571408)
21. 18F]FDDNP PETimages. J Neurol Neurosurg Psychiatry 81, 882-884.
22. Villemagne VL, Pike KE, Darby D, Maruff P, Savage G, Ng S, Ackermann U, Cowie TF, Currie J, Chan SG, Jones G, Tochon-Danguy H, O'Keefe G, Masters CL, Rowe CC (2008) Abeta deposits in older non-demented individuals with cogni-tive decline are indicative of preclinical Alzheimer's disease. Neuropsychologia 46, 1688-1697.
23. Aizenstein HJ, Nebes RD, Saxton JA, Price JC, Mathis CA, Tsopelas ND, Ziolko SK, James JA, Snitz BE, Houck PR, Bi W, Cohen AD, Lopresti BJ, DeKosky ST, Halligan EM, Klunk WE (2008) Frequent amyloid deposition without sig-nificant cognitive impairment among the elderly. Arch Neurol 65, 1509-1517.
24. Kosaka T, Imagawa M, Seki K, Arai H, Sasaki H, Tsuji S, Asami-Odaka A, Fukushima T, Imai K, Iwatsubo T (1997) The β-APP717 Alzheimer mutation increases the percentage of plasma amyloid-β protein ending at Aβ-42(43). Neurology 48, 741-745. (Pubitemid 27120117)
25. Scheuner D, Eckman C, Jensen M, Song X, Citron M, Suzuki N, Bird TD, Hardy J, Hutton M, Kukull W, Larson E, Levy-Lahad L, Viitanen M, Peskind E, Poorkaj P, Schellenberg G, Tanzi R, Wasco W, Lannfelt L, Selkoe D, Younkin S (1996) Secreted amyloid [beta]-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. Nat Med 2, 864-870. (Pubitemid 26296755)
26. Fukumoto H, Tennis M, Locascio JJ, Hyman BT, Growdon JH, Irizarry MC (2003) Age but not diagnosis is the main predictor of plasma amyloid β-protein levels. Arch Neurol 60, 958-964. (Pubitemid 36858355)
27. Vanderstichele H, Van Kerschaver E, Hesse C, Davidsson P, Buyse MA, Andreasen N, Minthon L, Wallin A, Blennow K, Vanmechelen E (2000) Standardization of measurement of beta-amyloid((1-42)) in cerebrospinal fluid and plasma. Amyloid 7, 245-258.
28. Tamaoka A, Fukushima T, Sawamura N, Ishikawa K, Oguni E, Komatsuzaki Y, Shoji S (1996) Amyloid β protein in plasma from patients with sporadic Alzheimer's disease. JNeurol Sci 141, 65-68. (Pubitemid 26297732)
29. Mayeux R, Honig LS, Tang MX, Manly J, Stern Y, Schupf N, Mehta PD (2003) Plasma Aβ40 and Aβ42 and Alzheimer's disease: relation to age, mortality, and risk. Neurology 61, 1185-1190. (Pubitemid 37377535)
30. Mayeux R, Tang MX, Jacobs DM, Manly J, Bell K, Merchant C, Small SA, Stern Y, Wisniewski HM, Mehta PD (1999) Plasma amyloid beta-peptide 1-42 and incipient Alzheimer's disease. Ann Neurol 46, 412-416. (Pubitemid 29416281)
31. van Oijen M, Hofman A, Soares HD, Koudstaal PJ, Breteler MM (2006) Plasma Abeta(1-40) and Abeta(1-42) andthe risk of dementia: a prospective case-cohort study. Lancet Neurol 5, 655-660. (Pubitemid 44062411)
32. Sundelof J, Giedraitis V, Irizarry MC, Sundstrom J, Ingelsson E, Ronnemaa E, Arnlov J, Gunnarsson MD, Hyman BT, Basun H, Ingelsson M, Lannfelt L, Kilander L (2008) Plasma beta amyloid and the risk of Alzheimer disease and dementia in elderly men. Arch Neurol 65, 256-263.
33. Graff-Radford NR, Crook JE, Lucas J, Boeve BF, Knopman DS, Ivnik RJ, Smith GE, Younkin LH, Petersen RC, Younkin SG (2007) Association of low plasma Abeta42/Abeta40 ratios with increased imminent risk for mild cognitive impairment and Alzheimer disease. Arch Neurol 64, 354-362. (Pubitemid 46425689)
34. Roher AE, Esh CL, Kokjohn TA, Castano EM, Van Vickle GD, Kalback WM, Patton RL, Luehrs DC, Daugs ID, Kuo YM, Emmerling MR, Soares H, Quinn JF, Kaye J, Connor DJ, Silverberg NB, Adler CH, Seward JD, Beach TG, Sabbagh MN (2009) Amyloid beta peptides in human plasma and tissues and their significance for Alzheimer's disease. Alzheimers Dement 5, 18-29.
35. Mehta PD, Pirttila T, Mehta SP, Sersen EA, Aisen PS, Wisniewski HM (2000) Plasma and cerebrospinal fluid levels of amyloid beta proteins 1-40 and 1-42 in Alzheimer disease. Arch Neurol 57, 100-105. (Pubitemid 30027637)
36. Freeman SH, Raju S, Hyman BT, Frosch MP, Irizarry MC (2007) Plasma A beta levels do not reflect brain A beta levels. J Neuropathol Exp Neurol 66, 264-271. (Pubitemid 46559019)
37. Ray S, Britschgi M, Herbert C, Takeda-Uchimura Y, Boxer A, Blennow K, Friedman LF, Galasko DR, Jutel M, Karydas A, Kaye JA, Leszek J, Miller BL, Minthon L, Quinn JF, Rabinovici GD, Robinson WH, Sabbagh MN, So YT, Sparks DL, Tabaton M, Tinklenberg J, Yesavage JA, Tibshirani R, Wyss-Coray T (2007) Classification and prediction of clini-cal Alzheimer's diagnosis based on plasma signaling proteins. Nat Med 13, 1359-1362. (Pubitemid 350073592)
38. Thambisetty M, Simmons A, Velayudhan L, Hye A, Campbell J, Zhang Y, Wahlund LO, Westman E, Kinsey A, Guntert A, Proitsi P, Powell J, Causevic M, Killick R, Lunnon K, Lynham S, Broadstock M, Choudhry F, Howlett DR, Williams RJ, Sharp SI, Mitchelmore C, Tunnard C, Leung R, Foy C, O'Brien D, Breen G, Furney SJ, Ward M, Kloszewska I, Mecocci P, Soininen H, Tsolaki M, Vellas B, Hodges A, Murphy DG, Parkins S, Richardson JC, Resnick SM, Ferrucci L, Wong DF, Zhou Y, Muehlboeck S, Evans A, Francis PT, Spenger C, Lovestone S (2010) Association of plasma clus-terin concentration with severity, pathology, and progression in Alzheimer disease. Arch Gen Psychiatry 67, 739-748.
39. Simonsen AH, McGuire J, Podust VN, Davies H, Minthon L, Skoog I, Andreasen N, Wallin A, Waldemar G, Blennow K (2008) Identification of a novel panel of cerebrospinal fluid biomarkers for Alzheimer's disease. Neurobiol Aging 29, 961-968. (Pubitemid 351697984)
40. Qin W, Ho L, Wang J, Peskind E, Pasinetti GM (2009) S100A7, a novel Alzheimer's disease biomarker with non-amyloidogenic α-secretase activity acts via selective pro-motion of ADAM-10. PLoS ONE 4, e4183.
41. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical-diagnosis of Alzheimer's disease-Report of the NINCDS-ADRDA Work Group under the Auspices of Department of Health and Human Services task force on Alzheimer's disease. Neurology 34, 939-944. (Pubitemid 14076461)
42. Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E (1999) Mild cognitive impairment-Clinical char-acterization and outcome. Arch Neurol 56, 303-308. (Pubitemid 29120227)
43. Delis D, Kramer J, Kaplan E, Ober B (2000) California Verbal Learning Test-Second Edition, The Psychological Corpora-tion, San Antonio, TX.
44. Folstein MF, Folstein SE, McHugh PR (1975) Mini-Mental State-practical method for grading cognitive state of patients for clinician. J Psychiatric Res 12, 189-198.
45. Benjamini Y, Hochberg Y (1995) Controlling the false dis-covery rate-A practical and powerful approach to multiple testing. J Royal Stat Soc Series B-Methodol 57, 289-300.
46. Wold H (1994) PLS for Multivariate linear modeling. In Chemometric Methods in Molecular Design: Methods and Principles in Medicinal Chemistry, van der Waterbeemd H, ed. Verlag-Chemie, Weinheim, Germany.
47. Kapaki E, Kilidireas K, Paraskevas GP, Michalopoulou M, Patsouris E (2001) Highly increased CSF tau protein and decreased β-amyloid (1-42) in sporadic CJD: a discrimination from Alzheimer's disease? J Neurol Neurosurg Psychiatry 71, 401-403. (Pubitemid 32772543)
48. Blennow K, Hampel H (2003) CSF markers for incipient Alzheimer's disease. Lancet Neurol 2, 605-613. (Pubitemid 37162569)
49. Andreasen N, Minthon L, Davidsson P, Vanmechelen E, Vanderstichele H, Winblad B, Blennow K (2001) Evalua-tion of CSF-tau and CSF-Aβ42 as diagnostic markers for Alzheimer disease in clinical practice. Arch Neurol 58, 373-379. (Pubitemid 32217453)
50. Riemenschneider M, Lautenschlager N, Wagenpfeil S, Diehl J, Drzezga A, Kurz A (2002) Cerebrospinal fluid tau and β-amyloid 42 proteins identify Alzheimer disease in subjects with mild cognitive impairment. Arch Neurol 59, 1729-1734. (Pubitemid 35340483)
51. Welge V, Fiege O, Lewczuk P, Mollenhauer B, Esselmann H, Klafki HW, Wolf S, Trenkwalder C, Otto M, Kornhuber J, Wiltfang J, Bibl M (2009) Combined CSF tau, p-tau181 and amyloid-beta 38/40/42 for diagnosing Alzheimer's disease. J Neural Transm 116, 203-212.
52. 11C]PIB in a nondemented population: Poten-tial antecedent marker of Alzheimer disease. Neurology 67, 446-452. (Pubitemid 44214969)
53. Sjögren M, Davidsson P, Gottfries J, Vanderstichele H, Edman AA, Vanmechelen E, Wallin A, Blennow K (2001) The cere-brospinal fluid levels of tau, growth-associated protein-43 and soluble amyloid precursor protein correlate in Alzheimer's disease, reflecting a common pathophysiological process. Dement Geriatr Cogn Disord 12, 257-264. (Pubitemid 32429725)
54. Formichi P, Battisti C, Radi E, Federico A (2006) Cere-brospinal fluid tau, Aβ, and phosphorylated tau protein for the diagnosis of Alzheimer's disease. J Cell Physiol 208, 39-46. (Pubitemid 43848987)